Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months.
Nomura Y, Sawahata M, Nakamura Y, Koike R, Katsube O, Hagiwara K, Niho S, Masuda N, Tanaka T, Sugiyama K. Nomura Y, et al. Among authors: masuda n. Vaccines (Basel). 2021 Dec 18;9(12):1500. doi: 10.3390/vaccines9121500. Vaccines (Basel). 2021. PMID: 34960246 Free PMC article.
Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.
Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Miyamoto A, et al. Sci Rep. 2024 May 3;14(1):10162. doi: 10.1038/s41598-024-60833-w. Sci Rep. 2024. PMID: 38702426 Free PMC article.
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: masuda n. Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575-5. Online ahead of print. Breast Cancer. 2024. PMID: 38642245
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T, Iwamoto T, Niikura N, Watanabe K, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S. Takeshita T, et al. Among authors: masuda n. ESMO Open. 2024 Apr;9(4):102385. doi: 10.1016/j.esmoop.2024.102385. Epub 2024 Feb 21. ESMO Open. 2024. PMID: 38387111 Free PMC article.
1,173 results